找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Hepatobiliary Cancers: An Interdisciplinary Approach; Nima Rezaei Book 2023 The Editor(s) (if applicable) and The Author(s), under exclusi

[復(fù)制鏈接]
樓主: 鳴叫大步走
31#
發(fā)表于 2025-3-26 21:52:43 | 只看該作者
32#
發(fā)表于 2025-3-27 02:25:47 | 只看該作者
33#
發(fā)表于 2025-3-27 08:44:02 | 只看該作者
Liver Cancer and the Curative Potential of Nanomedicine,the diagnosis occurs frequently at a late stage, where treatment options are limited. Immunotherapy based on targeting checkpoint inhibitors, which unleashes the break of antitumor immunity, works only for a minority of patients. This might partly be owed to the tolerogenic function of the liver. Na
34#
發(fā)表于 2025-3-27 13:02:52 | 只看該作者
35#
發(fā)表于 2025-3-27 16:58:43 | 只看該作者
Drug Resistance in Hepatocellular Carcinoma,e acquired drug resistance increasingly affects the management of HCC patients. Researchers have focused on drug resistance for many years and identified complex regulatory networks involved in this issue. In this chapter, the significant research progress regarding mechanisms underlying HCC drug re
36#
發(fā)表于 2025-3-27 19:27:47 | 只看該作者
Liver Stereotactic Body Radiotherapy (SBRT),organs. In addition, these patients have had worse tumor outcomes when new immunotherapies have been tested in clinical trials, together suggesting there is something especially immunosuppressive about the liver tissue. Initial preclinical and translational studies have brought some light into this
37#
發(fā)表于 2025-3-28 00:17:22 | 只看該作者
38#
發(fā)表于 2025-3-28 02:40:07 | 只看該作者
39#
發(fā)表于 2025-3-28 09:16:34 | 只看該作者
40#
發(fā)表于 2025-3-28 12:43:51 | 只看該作者
Liver Cancer: Interdisciplinary Approach,nvolving multiple signaling pathways such as VEGFR, EGFR, Raf/MEK/ERK, PI3K/AKT, and Wnt. Chronic hepatitis B virus infection is the most common cause. Combining the high-risk factors, imaging features and serological molecular markers of liver cancer, biopsy or surgical resection of liver space-occ
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-12 19:55
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
诏安县| 大同市| 江华| 昌吉市| 松滋市| 阿拉善左旗| 汉阴县| 土默特右旗| 大港区| 年辖:市辖区| 溆浦县| 平阳县| 安西县| 新巴尔虎右旗| 沐川县| 博湖县| 两当县| 宜君县| 武定县| 诸暨市| 武川县| 聂拉木县| 宁明县| 中宁县| 平武县| 潢川县| 茌平县| 绥化市| 琼结县| 墨脱县| 和林格尔县| 安徽省| 易门县| 闽清县| 彭山县| 敦化市| 黎平县| 台州市| 潮州市| 赤城县| 滨州市|